Last reviewed · How we verify
Daily Liraglutide for Nicotine Dependence (DAL)
This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain. In this double-blind, placebo-controlled, parallel arm pilot study, overweight and obese smokers (N=40; 20 female and 20 male) will be randomized to 32 weeks of liraglutide or placebo and undergo 8 sessions of smoking cessation behavioral counseling. Outcomes are smoking abstinence and weight change.
Details
| Lead sponsor | Rebecca Ashare |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 40 |
| Start date | Thu Nov 29 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed May 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Smoking Cessation
- Weight, Body
Interventions
- Liraglutide
- Placebo
- Smoking Cessation Counseling
Countries
United States